Skip to main content

Research Repository

Advanced Search

All Outputs (91)

A multi-centre study using comprehensive geriatric assessment to determine differences between older women with operable breast cancer undergoing surgery or non-operative treatment (2020)
Journal Article
Parks, R., Howard, P., Zahit, R., Kayani, A., Lakshmanan, R., Tang, S., …Cheung, K. (2020). A multi-centre study using comprehensive geriatric assessment to determine differences between older women with operable breast cancer undergoing surgery or non-operative treatment. Breast Cancer Research and Treatment, 180(2), 527-596. https://doi.org/10.1007/s10549-019-05514-3

Aims/Objectives: Shared decision making on the choice of treatment for older women with breast cancer involves many factors. Comprehensive geriatric assessment (CGA) is recognised to have a role in older patients with cancer, but how this should be u... Read More about A multi-centre study using comprehensive geriatric assessment to determine differences between older women with operable breast cancer undergoing surgery or non-operative treatment.

Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy (2019)
Journal Article
Luveta, J., Parks, R. M., Heery, D. M., Cheung, K., & Johnston, S. J. (2020). Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy. Oncology and Therapy, 8, 1-11. https://doi.org/10.1007/s40487-019-00105-0

Invasive lobular carcinoma comprises 10–15% of all breast cancers and is increasingly recognised as a distinct and understudied disease compared with the predominant histological subtype, invasive ductal carcinoma. Hallmarks of invasive lobular carci... Read More about Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy.

Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT) (2019)
Journal Article
Robertson, J. F., Coleman, R. E., Cheung, K., Evans, A., Holcombe, C., Skene, A., …Gee, J. M. (2020). Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT). Clinical Cancer Research, 26(7), 1574-1585. https://doi.org/10.1158/1078-0432.CCR-19-3053

© 2020 American Association for Cancer Research Inc.. All rights reserved. Purpose: The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therape... Read More about Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT).

Personalising Care in the Older Woman with Primary Breast Cancer (2019)
Journal Article
Parks, R. M., & Cheung, K. L. (2019). Personalising Care in the Older Woman with Primary Breast Cancer. Annals of the Academy of Medicine, Singapore, 48(11), 370-375

The incidence of breast cancer increases with age. Despite this, most research in the field is targeted at younger patients. Age-specific guidelines are not widely referred to and guidelines which allude to the older woman as an individual are based... Read More about Personalising Care in the Older Woman with Primary Breast Cancer.

Early-Stage Breast Cancer in Older Adults (2019)
Book Chapter
Cheung, K., Livi, L., & Brain, E. (2019). Early-Stage Breast Cancer in Older Adults. In M. Extermann (Ed.), Geriatric Oncology, 1-10. Springer. doi:10.1007/978-3-319-44870-1_33-1

Breast cancer is the most common cancer afflicting women worldwide. Its incidence peaks around 70, while mortality increases greatly after 75 years old. Given the competing risks on mortality with multimorbidities, geriatric assessment is a leitmotiv... Read More about Early-Stage Breast Cancer in Older Adults.

Liver kinase B1—a potential therapeutic target in hormone-sensitive breast cancer in older women (2019)
Journal Article
Syed, B. M., Green, A. R., Morgan, D. A., Ellis, I. O., & Cheung, K. (2019). Liver kinase B1—a potential therapeutic target in hormone-sensitive breast cancer in older women. Cancers, 11(2), 1-17. https://doi.org/10.3390/cancers11020149

Background: The role of liver kinase B1 (LKB1), a serine/threonine kinase, has been described in the development of PeutzJagher’s syndrome, where a proportion (~45%) of patients have developed breast cancer in their lifetime. Cell line studies have l... Read More about Liver kinase B1—a potential therapeutic target in hormone-sensitive breast cancer in older women.

Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition (2018)
Journal Article
Chen, X., Low, K. H., Alexander, A., Jiang, Y., Karakas, C., Hess, K. R., …Keyomarsi, K. (2018). Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition. Clinical Cancer Research, https://doi.org/10.1158/1078-0432.ccr-18-1446

Purpose: Poor prognosis in triple-negative breast cancer (TNBC) is due to an aggressive phenotype and lack of biomarker-driven targeted therapies. Overexpression of cyclin E and phosphorylated-CDK2 are correlated with poor survival in TNBC patients,... Read More about Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition.

Endocrine therapy for breast cancer: a model of hormonal manipulation (2018)
Journal Article
Johnston, S. J., & Cheung, K. (in press). Endocrine therapy for breast cancer: a model of hormonal manipulation. Oncology and Therapy, https://doi.org/10.1007/s40487-018-0062-x

Oestrogen receptor (ER) is the driving transcription factor in 70% of breast cancer. Endocrine therapies targeting the ER represent one of the most successful anticancer strategies to date. In the clinic, novel targeted agents are now being exploited... Read More about Endocrine therapy for breast cancer: a model of hormonal manipulation.

Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort (2018)
Journal Article
Schuil, H., Derks, M., Liefers, G., Portielje, J., van de Velde, C., Syed, B., …Bastiaannet, E. (in press). Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort. Journal of Geriatric Oncology, https://doi.org/10.1016/j.jgo.2018.05.004

Objective: Clinical trials investigating breast cancer treatment often exclude or misrepresent older adults. This study compares treatment patterns and survival of older women diagnosed with breast cancer between a Dutch and a British observational c... Read More about Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort.

Fulvestrant for the treatment of advanced breast cancer (2018)
Journal Article
Blackburn, S. A., Parks, R. M., & Cheung, K. (2018). Fulvestrant for the treatment of advanced breast cancer. Expert Review of Anticancer Therapy, 18(7), 619-628. https://doi.org/10.1080/14737140.2018.1473038

Introduction: The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degr... Read More about Fulvestrant for the treatment of advanced breast cancer.

Optimising endocrine therapy in postmenopausal women with advanced breast cancer (2018)
Journal Article
Yau, T. H. L., & Cheung, K. (2018). Optimising endocrine therapy in postmenopausal women with advanced breast cancer. Endocrine-Related Cancer, 25(7), 705-721. https://doi.org/10.1530/ERC-18-0021

Hormone receptor-positive breast cancer is commonly treated with endocrine therapy; however, overtime cancer cells can develop endocrine resistance. This review aims to document combination therapy and sequential therapy in the use of endocrine agent... Read More about Optimising endocrine therapy in postmenopausal women with advanced breast cancer.

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer (2018)
Journal Article
Robertson, J. F., Cheung, K., Noguchi, S., Shao, Z., Degboe, A., Lichfield, J., …Ellis, M. J. (2018). Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. European Journal of Cancer, 94, https://doi.org/10.1016/j.ejca.2018.02.026

Background The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) local... Read More about Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.

BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer (2018)
Journal Article
Gong, C., Man, E. P., Tsoi, H., Lee, T. K., Paul, L., Mak, S., …Khoo, U. (2018). BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer. Clinical Cancer Research, 24(15), 3681-3691. https://doi.org/10.1158/1078-0432.CCR-17-2259

Purpose: Adjuvant tamoxifen treatment revolutionized the management of estrogen receptor (ER) positive breast cancers to prevent cancer recurrence; however drug resistance compromises its clinical efficacy. The mechanisms underlying tamoxifen resista... Read More about BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer.

Oestrogen receptor negative early operable primary breast cancer in older women—biological characteristics and long-term clinical outcome (2017)
Journal Article
Syed, B. M., Morgan, D., Setty, T., Green, A. R., Paish, E. C., Ellis, I. O., & Cheung, K. (2017). Oestrogen receptor negative early operable primary breast cancer in older women—biological characteristics and long-term clinical outcome. PLoS ONE, 12(12), Article e0188528. https://doi.org/10.1371/journal.pone.0188528

Background Older women are at the greatest risk of breast cancer development and a considerable number present with comorbidities. Although the majority of breast cancers in this age group express oestrogen receptor (ER), which makes endocrine the... Read More about Oestrogen receptor negative early operable primary breast cancer in older women—biological characteristics and long-term clinical outcome.

4th symposium on primary breast cancer in older women. Theme: putting personalized care into practice (held: 3 March 2017) (2017)
Journal Article
Cheung, K., Morgan, D., Brain, E., Poortmans, P., Parks, R., Korc-Grodzicki, B., …Wijayatunga, R. (in press). 4th symposium on primary breast cancer in older women. Theme: putting personalized care into practice (held: 3 March 2017). Breast Cancer Management, https://doi.org/10.2217/bmt-2017-0016

Following the inception in 2010, the University of Nottingham hosted the 4th Symposium on Primary Breast Cancer in Older Women, under the auspices of the International Society of Geriatric Oncology, in March 2017, at East Midlands Conference Centre.... Read More about 4th symposium on primary breast cancer in older women. Theme: putting personalized care into practice (held: 3 March 2017).

A continuing mission to optimize the care of older women with breast cancer (2017)
Journal Article
Cheung, K. (2017). A continuing mission to optimize the care of older women with breast cancer. Geriatrics, 2(4), Article 37. https://doi.org/10.3390/geriatrics2040037

The majority of cases of breast cancer occur in the older population who are often un-represented in clinical trials. Given the growing ageing population globally, it becomes urgent and important to identify an optimal approach so that older women wi... Read More about A continuing mission to optimize the care of older women with breast cancer.

Tumour boards in geriatric oncology (2017)
Journal Article
Wildes, T. M., O'Donovan, A., Colloca, G. F., & Cheung, K. (2018). Tumour boards in geriatric oncology. Age and Ageing, 47(2), 168-170. https://doi.org/10.1093/ageing/afx171

Multidisciplinary tumour board (MDT) is an integral part of cancer treatment planning. Although no definite survival benefits have yet been shown by mostly observational studies, other benefits of MDT have been identified. Traditionally the MDT invol... Read More about Tumour boards in geriatric oncology.

Controversial issues in the management of older adults with early breast cancer (2017)
Journal Article
Mislang, A. R., Cheung, K., Hamaker, M. E., Kunkler, I., Markopoulos, C., Orecchia, R., …Biganzoli, L. (in press). Controversial issues in the management of older adults with early breast cancer. Journal of Geriatric Oncology, https://doi.org/10.1016/j.jgo.2017.05.004

It is well recognized that the incidence of breast cancer increases significantly with age. Despite this, older people remain under-represented in many clinical trials and their management relies on extrapolation of data from younger patients. Provid... Read More about Controversial issues in the management of older adults with early breast cancer.

Axillary reverse mapping in N0 patients requiring sentinel lymph node biopsy: a systematic review of the literature and necessity of a randomised study (2017)
Journal Article
Parks, R., & Cheung, K. (2017). Axillary reverse mapping in N0 patients requiring sentinel lymph node biopsy: a systematic review of the literature and necessity of a randomised study. Breast, 33, https://doi.org/10.1016/j.breast.2017.02.019

Objectives: Axillary reverse mapping (ARM) is a technique to map and preserve arm lymphatics which may be damaged during surgery, resulting in lymphoedema. This work systematically reviews the incidence of lymphoedema following sentinel lymph node bi... Read More about Axillary reverse mapping in N0 patients requiring sentinel lymph node biopsy: a systematic review of the literature and necessity of a randomised study.